<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39143474</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2662-7671</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC complementary medicine and therapies</Title><ISOAbbreviation>BMC Complement Med Ther</ISOAbbreviation></Journal><ArticleTitle>How fragile the positive results of Chinese herbal medicine randomized controlled trials on irritable bowel syndrome are?</ArticleTitle><Pagination><StartPage>300</StartPage><MedlinePgn>300</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">300</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12906-024-04561-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The fragility index (FI), which is the minimum number of changes in status from "event" to "non-event" resulting in a loss of statistical significance, serves as a significant supplementary indicator for clinical physicians in interpreting clinical trial results and aids in understanding the outcomes of randomized controlled trials (RCTs). In this systematic literature survey, we evaluated the FI for RCTs evaluating Chinese herbal medicine (CHM) for irritable bowel syndrome (IBS), and explored potential associations between study characteristics and the robustness of RCTs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive search was conducted in four databases in Chinese and four databases in English from their inception to January 1, 2023. RCTs encompassed 1:1 ratio into two parallel arms and reported at least one binary outcome that demonstrated statistical significance were included. FI was calculated by the iterative reduction of a target outcome event in the treatment group and concomitant subtraction of a non-target event from that group, until positive significance (defined as P&#x2009;&lt;&#x2009;0.05 by Fisher's exact test) is lost. The lower the FI (minimum 1) of a trial outcome, the more fragile the positive result of the outcome was. Linear regression models were adopted to explore influence factors of the value of FI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 30 trials from 2 4118 potentially relevant citations were finally included. The median FI of total trials included was 1.5 (interquartile range [IQR], 1-5), and half of the trials (n&#x2009;=&#x2009;15) had a FI equal to 1. In 12 trials (40%), the total number of participants lost to follow-up surpassed the respective FI. The study also identified that increased FI was significantly associated with no TCM syndrome differentiation for inclusion criteria of the patients, larger total sample size, low risk of bias, and larger numbers of events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The majority of CHM IBS RCTs with positive results were found to be fragile. Ensuring adequate sample size, scientifically rigorous study design, proper control of confounding factors, and a quality control calibration for consistency of TCM diagnostic results among clinicians should be addressed to increase the robustness of the RCTs. We recommend reporting the FI as one of the components of sensitivity analysis in future RCTs to facilitate the assessment of the fragility of trials.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Minjing</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jinghan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yingqiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yilin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Qi-Huang Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhihan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Meijun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Yunci</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Qianyun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fei</LastName><ForeName>Yutong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. feiyt@bucm.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. feiyt@bucm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Complement Med Ther</MedlineTA><NlmUniqueID>101761232</NlmUniqueID><ISSNLinking>2662-7671</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chinese herbal medicine</Keyword><Keyword MajorTopicYN="N">Fragility index</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">Research methodology</Keyword></KeywordList><CoiStatement>The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39143474</ArticleId><ArticleId IdType="pmc">PMC11323352</ArticleId><ArticleId IdType="doi">10.1186/s12906-024-04561-8</ArticleId><ArticleId IdType="pii">10.1186/s12906-024-04561-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Exp&#xf3;sito-Ruiz M, P&#xe9;rez-Vicente S, Rivas-Ruiz F. Statistical inference: hypothesis testing. Allergol Immunopathol (Madr). 2010;38(5):266&#x2013;77. 10.1016/j.aller.2010.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aller.2010.06.003</ArticleId><ArticleId IdType="pubmed">20817378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmukaddam SB. Interpreting statistical hypothesis testing results in clinical research. J Ayurveda Integr Med. 2012;3(2):65&#x2013;9. 10.4103/0975-9476.96518</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0975-9476.96518</ArticleId><ArticleId IdType="pmc">PMC3371560</ArticleId><ArticleId IdType="pubmed">22707861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew MJ. Principles: when there should be no difference&#x2013;how to fail to reject the null hypothesis. Trends Pharmacol Sci. 2006;27(5):274&#x2013;8. 10.1016/j.tips.2006.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2006.03.006</ArticleId><ArticleId IdType="pubmed">16595154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA. Hypothesis and hypothesis testing in the clinical trial. J Clin Psychiatry. 2001;62:5&#x2013;8. discussion 9&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11379832</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J. Primary question and hypothesis testing in Randomized Controlled clinical trials. Shanghai Arch Psychiatry. 2016;28(3):177&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434306</ArticleId><ArticleId IdType="pubmed">28638190</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves N, Barnett AG, Burn E, Cook D. Smaller clinical trials for decision making; a case study to show p-values are costly. F1000Res. 2018;7:1176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9555245</ArticleId><ArticleId IdType="pubmed">36262673</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsushima E. Interpreting results from statistical hypothesis testing: understanding the appropriate P-value. Phys Ther Res. 2022;25(2):49&#x2013;55. 10.1298/ptr.R0019</Citation><ArticleIdList><ArticleId IdType="doi">10.1298/ptr.R0019</ArticleId><ArticleId IdType="pmc">PMC9437930</ArticleId><ArticleId IdType="pubmed">36118788</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67(6):622&#x2013;8. 10.1016/j.jclinepi.2013.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2013.10.019</ArticleId><ArticleId IdType="pubmed">24508144</ArticleId></ArticleIdList></Reference><Reference><Citation>Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med. 2003;254(2):105&#x2013;13. 10.1046/j.1365-2796.2003.01201.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2796.2003.01201.x</ArticleId><ArticleId IdType="pubmed">12859691</ArticleId></ArticleIdList></Reference><Reference><Citation>Evaniew N, Files C, Smith C, et al. The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey. Spine J. 2015;15(10):2188&#x2013;97. 10.1016/j.spinee.2015.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2015.06.004</ArticleId><ArticleId IdType="pubmed">26072464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzbarsky JJ, Khormaee S, Daluiski A. The Fragility Index in Hand Surgery Randomized Controlled Trials. J Hand Surg Am. 2019;44(8):698.e691-698.e697.</Citation><ArticleIdList><ArticleId IdType="pubmed">30420197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgeon EE, Young PJ, Bellomo R, Mucchetti M, Lembo R, Landoni G. The Fragility Index in Multicenter Randomized controlled critical care trials. Crit Care Med. 2016;44(7):1278&#x2013;84. 10.1097/CCM.0000000000001670</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001670</ArticleId><ArticleId IdType="pubmed">26963326</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnoyers A, Wilson BE, Nadler MB, Amir E. Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours. Cancer Treat Rev. 2021;94:102167. 10.1016/j.ctrv.2021.102167</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2021.102167</ArticleId><ArticleId IdType="pubmed">33652263</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter SD, Thabane L, Briel M. The fragility of trial results involves more than statistical significance alone. J Clin Epidemiol. 2020;124:34&#x2013;41. 10.1016/j.jclinepi.2020.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.02.011</ArticleId><ArticleId IdType="pubmed">32298777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Zhou K, Fan J, Sun S. Traditional Chinese medicine: potential approaches from modern dynamical complexity theories. Front Med. 2016;10(1):28&#x2013;32. 10.1007/s11684-016-0434-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-016-0434-2</ArticleId><ArticleId IdType="pubmed">26809465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu AP, Jia HW, Xiao C, Lu QP. Theory of traditional Chinese medicine and therapeutic method of diseases. World J Gastroenterol. 2004;10(13):1854&#x2013;6. 10.3748/wjg.v10.i13.1854</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v10.i13.1854</ArticleId><ArticleId IdType="pmc">PMC4572216</ArticleId><ArticleId IdType="pubmed">15222022</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu C. The fundamental theory of traditional Chinese medicine and the consideration in its research strategy. Front Med. 2011;5(2):208&#x2013;11. 10.1007/s11684-011-0126-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-011-0126-x</ArticleId><ArticleId IdType="pubmed">21695627</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Zhu JJ, Li JC. The interpretation of human body in traditional Chinese medicine and its influence on the characteristics of TCM theory. Anat Rec (Hoboken). 2021;304(11):2559&#x2013;65. 10.1002/ar.24643</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.24643</ArticleId><ArticleId IdType="pubmed">34117702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Sun S, Peng CK. Applications of dynamical complexity theory in traditional Chinese medicine. Front Med. 2014;8(3):279&#x2013;84. 10.1007/s11684-014-0367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-014-0367-6</ArticleId><ArticleId IdType="pubmed">25204292</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. 10.1136/bmj.b2700</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Dumitrascu DL, Rome III. New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):237&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013448</ArticleId></ArticleIdList></Reference><Reference><Citation>Alt F, Chong PW, Teng E, Uebelhack R. Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the symptomatic improvement of irritable bowel syndrome: a Double-Blinded, randomised, placebo-controlled clinical trial. Phytother Res. 2017;31(7):1056&#x2013;62. 10.1002/ptr.5826</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5826</ArticleId><ArticleId IdType="pmc">PMC5518189</ArticleId><ArticleId IdType="pubmed">28508427</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome? Am J Gastroenterol. 2009;104(4):920&#x2013;2. 10.1038/ajg.2009.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2009.20</ArticleId><ArticleId IdType="pmc">PMC3895869</ArticleId><ArticleId IdType="pubmed">19293789</ArticleId></ArticleIdList></Reference><Reference><Citation>Portincasa P, Bonfrate L, Scribano ML, et al. Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. J Gastrointestin Liver Dis. 2016;25(2):151&#x2013;7. 10.15403/jgld.2014.1121.252.ccm</Citation><ArticleIdList><ArticleId IdType="doi">10.15403/jgld.2014.1121.252.ccm</ArticleId><ArticleId IdType="pubmed">27308645</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108&#x2013;31. 10.1053/gast.2002.37095</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2002.37095</ArticleId><ArticleId IdType="pubmed">12454866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. 10.1136/bmj.l4898</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunt M. Introduction to statistical modelling: linear regression. Rheumatology (Oxford). 2015;54(7):1137&#x2013;40. 10.1093/rheumatology/ket146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket146</ArticleId><ArticleId IdType="pubmed">23594471</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MS, Ochani RK, Shaikh A, et al. Fragility Index in Cardiovascular Randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2019;12(12):e005755. 10.1161/CIRCOUTCOMES.119.005755</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.119.005755</ArticleId><ArticleId IdType="pmc">PMC7962007</ArticleId><ArticleId IdType="pubmed">31822121</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado DR, Go CC, Huang BH, Domb BG. The Fragility Index of Hip Arthroscopy Randomized controlled trials: a systematic survey. Arthroscopy. 2021;37(6):1983&#x2013;9. 10.1016/j.arthro.2021.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2021.01.049</ArticleId><ArticleId IdType="pubmed">33539980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Li TQ, Wang L, et al. Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: a prospective, randomized, double-blind, placebo-controlled trial[J]. Chin Med J (Engl).2006;119(24):2114&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17199964</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil((R))) in the treatment of irritable bowel syndrome: A prospective double-blind placebo-controlled randomized trial[J]. Dig Liver Dis 2007;39(6):530&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SS, Xu WJ, Chen Z, et al. Short-term and medium-term clinical effect of liver dispersing with spleenstrengthening on irritable bowel syndrome dominated by diarrhea[J]. J Cap Med Uni 2009;30(4):436&#x2013;40.</Citation></Reference><Reference><Citation>Saito YA, Rey E, Almazar-Elder AE, et al. A randomized, double-blind, placebo-controlled trial of St John&#x2019;s Wort for treating irritable bowel syndrome[J]. Am J Gastroenterol. 2010;105(1):170&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19809408</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Zhang YN, Cai G, et al. A randomized, double-blinded and placebo-controlled trial of Chang Ji Tai Granule in treating diarrhea-predominant diarrhea[J]. ShangHai J Tradit Chin Med 2010;44(12):33&#x2013;6.</Citation></Reference><Reference><Citation>Zhang SS, Wang HB, Li ZH, et al. A multi-center randomized controlled study on syndrome differentiation oftraditional Chinese medicine in the treatment of diarrhea-predominant irritable bowel syndrome[J]. Chin J Integr Med. 2010;30(1):9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">20353023</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang XD, Li ZH, Li BS, et al. A randomized, double-blind, placebo-controlled clinical study of Chang&#x2019;an prescription 1 in the treatment of diarrhea-predominant irritable bowel syndrome[D]. Beijing Uni Chin Med. 2011.</Citation></Reference><Reference><Citation>Zhang W, Zhang ZL, Li L. Clinical Research Irritable Bowel Syndrome with the Treatment of Liver-Softening andSpleen-Nourishing Decoction[J]. Hubei J Trad Chin Med. 2013;35(05):12&#x2013;4.</Citation></Reference><Reference><Citation>Fu Q, Xu DS, Jiang SQ. Shugan Liqi Zhixie Tang in Treatment of 68 Patients with Diarrhea-predominant Irritable BowelSyndrome[J]. Chin J Exp Trad Med Form. 2013;19(16):301&#x2013;4.</Citation></Reference><Reference><Citation>Li XL, Su ZZ, Gu XD. Observation on the efficacy of Changyiqing in the treatment of irritable bowel syndrome withspleen deficiency and dampness syndrome[J]. Chin J Inte Trad Chin West Med Dig. 2014;22(8):475&#x2013;7.</Citation></Reference><Reference><Citation>Portincasa P, Bonfrate L, Scribano ML, et al. Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome[J]. J Gast Liv Dis. 2016;25(2):151&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27308645</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZW, Niu LJ, Su Q, et al. 100 cases of diarrhea-predominant irritable bowel syndrome treated with Anchangzhitongprescription combined with trimebutine[J]. Henan Trad chin Med. 2014;34(10):2015&#x2013;16.</Citation></Reference><Reference><Citation>Hu QP. Self Beneficial Intestinal Side Spleen Dampness Type of Adjuvant Therapy Clinical Observation IrritableBowel[J]. Mod Diag Treat. 2015(1):42&#x2013;3.</Citation></Reference><Reference><Citation>Cheng YY. Clinical study on the treatment of irritable bowel syndrome with liver stagnation and spleen deficiencywith Chaishao Tiaogan Decotion[D], Hebei Med Univ. 2015.</Citation></Reference><Reference><Citation>Alt F, Chong P-W, Teng E, et al. Evaluation of benefit and tolerability of IQP-CL-101 (Xanthofen) in the symptomaticimprovement of irritable bowel syndrome: a double-blinded, randomised, placebo-controlled clinical Trial[J].Phyto Res: PTR. 2017;31(7):1056&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518189</ArticleId><ArticleId IdType="pubmed">28508427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Tang TC, Wang Y, et al. Randomised clinical trial: tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome[J]. Ali Phar Thera. 2018;48(2):160&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">29856472</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang XD, Li B, Li ZH, et al. Therapeutic effect of chang&#x2019;an I recipe on irritable bowel syndrome with diarrhea: a multicenter randomized double-blind placebo-controlled clinical Trial [J]. Chin J Int Med. 2018;24(09):645&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">27487786</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng MW, Chen YB, Cao J. Clinical Observation on 35 Cases of Treating Diarrheal Irritable Bowel Syndrome with LiverStagnation and Spleen Deficiency with Changning Prescription[J]. Journal of Traditional Chinese Medicine.2019;60(19):1663&#x2013;1667.</Citation></Reference><Reference><Citation>Zeng P. Clinical study on the treatment of diarrhea-type irritable bowel syndrome with Shaoyang taiyin cold andheat benefit with Chaihu Guizhi Ganjiang Decoction[D]. Fujian Univ Trad Chin Med. 2019.</Citation></Reference><Reference><Citation>Chen X, Dai XT, Wu YL, et al. Clinical efficacy of An Chang Zhi Xie decotion in the treatment of diarrhea-type irritable bowel syndrome[J]. Inn Mongo J Trad Chin Med. 2020;39(9):8&#x2013;9.</Citation></Reference><Reference><Citation>Zhao XY. Clinical study on the treatment of diarrhea-type irritable bowel syndrome by adding flavors to Wei GuanDecoction[D]. Yunn Univ Trad Chin Med. 2020.</Citation></Reference><Reference><Citation>Zheng HP, Zhang ZB, Wei XP, et al. Effect of Addition and Subtraction Therapy of Xiaoyaosan Combined withSimotang to Gut-brain Axis of Patients with Irritable Bowel Syndrome with Predominant Constipation and Syndromeof Stagnation of Liver Qi[J]. Chin J Exp Trad Med Form. 2020;26(22):53&#x2013;58.</Citation></Reference><Reference><Citation>Bordbar G, Miri MB, Omidi M, et al. Efficacy and safety of a novel herbal medicine in the treatment of irritable bowel syndrome: a randomized double-blinded clinical Trial[J]. Gastro Res Prac. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273440</ArticleId><ArticleId IdType="pubmed">32565786</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu AP, Zhang HJ. Clinical study on the treatment of constipation-predominant irritable bowel syndrome with "yangmicro-knot" by Chaishao Zhizhu Decoction[D]. Fujian Univ Trad Chin Med. 2020.</Citation></Reference><Reference><Citation>Li YX. Clinical analysis of Liuwei Nengxiao capsule in the treatment of constipation-predominant irritable bowelsyndrome[J]. J Prac Trad Chin Med. 2021;37(12):2010&#x2013;2011.</Citation></Reference><Reference><Citation>Kong WQ. Evaluation of the clinical efficacy of Changkang prescription in the treatment of constipation-predominantirritable bowel syndrome and research on its mechanism of action[D]. Nanj Univ Chin Med. 2021.</Citation></Reference><Reference><Citation>Jin YL. Clinical study on the treatment of diarrhea-predominant irritable bowel syndrome with Xingpi HuashiDecoction[D]. Zhejiang Univ Trad Chin Med. 2021.</Citation></Reference><Reference><Citation>Guo LX, Qin TT, Gao J, et al. Study on the regulatory effect of Shenbei Guchang Capsule on the brain-gut bacteriaaxis in the treatment of diarrhea-predominant irritable bowel syndrome[J]. J Chin Med Mat. 2022;45(10):2502&#x2013;2506.</Citation></Reference><Reference><Citation>Zou JY, Tan HC, Wu C, et al. Analysis of the influencing factors of irritable bowel syndrome and the therapeutic effect of spleen-invigorating and astringent therapy in treating diarrhea od spleen-kidney yang deficiency syndrome[J].World J Inte Trad West Med. 2022;17(1):192&#x2013;195.</Citation></Reference><Reference><Citation>Wang YR, Fu WB, Sun YQ, et al. Clinical efficacy of tongxie yaofang on diarrhea-predominant irritable bowelsyndrome (IBS-D) patients with liver depression and spleen deficiency[J]. Chin J Exp Trad Med Form. 2022;28(9):97&#x2013;102.</Citation></Reference><Reference><Citation>Bertaggia L, Baiardo Redaelli M, Lembo R, et al. The Fragility Index in peri-operative randomised trials that reported significant mortality effects in adults. Anaesthesia. 2019;74(8):1057&#x2013;60. 10.1111/anae.14656</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.14656</ArticleId><ArticleId IdType="pubmed">31025706</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner M, Tritz D, Farahani C, Ross A, Hamilton T, Vassar M. The fragility of statistically significant results in otolaryngology randomized trials. Am J Otolaryngol. 2019;40(1):61&#x2013;6. 10.1016/j.amjoto.2018.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2018.10.011</ArticleId><ArticleId IdType="pubmed">30472124</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Lane A, Cooper C, Vassar M. The results of randomized controlled trials in Emergency Medicine are frequently fragile. Ann Emerg Med. 2019;73(6):565&#x2013;76. 10.1016/j.annemergmed.2018.10.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2018.10.037</ArticleId><ArticleId IdType="pubmed">30551894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaitoff A, Zheutlin A, Niforatos JD. The Fragility Index and Trial significance. JAMA Intern Med. 2020;180(11):1554. 10.1001/jamainternmed.2020.4787</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.4787</ArticleId><ArticleId IdType="pubmed">32955584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218&#x2013;28. 10.1001/jama.294.2.218</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.2.218</ArticleId><ArticleId IdType="pubmed">16014596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang GG, Lee W, Bausell B, Lao L, Handwerger B, Berman B. Variability in the traditional Chinese medicine (TCM) diagnoses and herbal prescriptions provided by three TCM practitioners for 40 patients with rheumatoid arthritis. J Altern Complement Med. 2005;11(3):415&#x2013;21. 10.1089/acm.2005.11.415</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/acm.2005.11.415</ArticleId><ArticleId IdType="pubmed">15992224</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida Andrade F, Schlechta Portella CF. Research methods in complementary and alternative medicine: an integrative review. J Integr Med. 2018;16(1):6&#x2013;13. 10.1016/j.joim.2017.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joim.2017.12.001</ArticleId><ArticleId IdType="pubmed">29397095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidani S. Rethinking the research-practice gap: relevance of the RCT to practice. Can J Nurs Res. 2004;36(3):7&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15551659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow JT, Lam K, Naeem A, Akanda ZZ, Si FF, Hodge W. The pathway to RCTs: how many roads are there? Examining the homogeneity of RCT justification. Trials. 2017;18(1):51. 10.1186/s13063-017-1804-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-017-1804-z</ArticleId><ArticleId IdType="pmc">PMC5288880</ArticleId><ArticleId IdType="pubmed">28148278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>